Hippocampus-sparing radiotherapy using volumetric modulated arc therapy (VMAT) to the primary brain tumor: the result of dosimetric study and neurocognitive function assessment

Table 3 Change of neurocognitive function (NCF) test at seven months from baseline

	Mean change from Baseline (%)^a	95% CI	Probability of deterioration^b(%)
MMSE	− 1.2	− 9.8 to 7.4	3.8
SVLT-Total recall	−7.7	−19.6 to 4.2	7.7
SVLT-Delayed recall	−9.2^c	− 25.4 to 7.0^c	7.7
SVLT-Recognition	−3.4	−12.7 to 5.8	11.5
RCFT-COPY	1.8	−7.4 to 11.1	24
RCFT-Immediate recall	−8.1	−36.2 to 20.0	8
RCFT-Delayed recall	−25.2^d	− 52.8 to 2.5^d	8
RCFT-Recognition	−3.8	−11.2 to 4.0	12

MMSE Mini-Mental State Examination, SVLT Seoul Verbal Learning Test, RCFT Rey Complex Figure Test and Recognition Trial
^aΔNCF = (NCF_B-NCF_F)/NCF_B, Where B = baseline and F = follow-up, (Minus change indicate improved NCF)
^bDeterioration in NCF test from baseline defined as drop of z-score 1.5 (drop of 1.5 standard deviation)
^cExclusion of one patient with 0 test result at baseline
^dExclusion of one patient who could not be assessed at baseline

ISSN: 1748-717X